Rankings
▼
Calendar
ALNY Q1 2025 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
ALNY
Alnylam Pharmaceuticals, Inc.
$43B
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$594M
+20.2% YoY
Gross Profit
$523M
88.0% margin
Operating Income
$18M
3.0% margin
Net Income
-$57M
-9.7% margin
EPS (Diluted)
$-0.44
QoQ Revenue Growth
+0.2%
Cash Flow
Operating Cash Flow
-$118M
Free Cash Flow
-$127M
Stock-Based Comp.
$57M
Balance Sheet
Total Assets
$4.2B
Total Liabilities
$4.1B
Stockholders' Equity
$115M
Cash & Equivalents
$1.0B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$594M
$494M
+20.2%
Gross Profit
$523M
$428M
+22.1%
Operating Income
$18M
-$43M
+141.6%
Net Income
-$57M
-$66M
+12.8%
Revenue Segments
Product
$469M
80%
GIVLAARI
$67M
11%
ONPATTRO
$49M
8%
Geographic Segments
UNITED STATES
$198M
64%
Europe
$80M
26%
Non-US Or Europe
$32M
10%
← FY 2025
All Quarters
Q2 2025 →